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Background: The presence of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
(NSCLC) is associated with increased radiosensitivity in vitro. However, the results from clinical studies regarding the
radiosensitivity in NSCLC with mutant EGFR are inconclusive. We retrospectively analyzed our NSCLC patients who
had been regularly followed up by imaging studies after irradiation for brain metastases, and investigated the
impact of EGFR mutations on radiotherapy (RT).
Methods: Forty-three patients with brain metastases treated with RT, together with EGFR mutation status,
demographics, smoking history, performance status, recursive partitioning analysis (RPA) class, tumor characteristics,
and treatment modalities, were included. Radiological images were taken at 1 to 3 months after RT, and 3 to
6 months thereafter. Radiographic response was evaluated by RECIST criteria version 1.1 according to the
intracranial images before and after RT. Log-rank test and Cox regression model were used to correlate EGFR
mutation status and other clinical features with intracranial radiological progression-free survival (RPFS) and overall
survival (OS).
Results: The median follow-up duration was 15 months. Patients with mutant EGFR had higher response rates to
brain RT than those with wild-type EGFR (80% vs. 46%; p = 0.037). Logistic regression analysis showed that EGFR
mutation status is the only predictor for treatment response (p = 0.032). The median intracranial RPFS was
18 months (95% CI = 8.33-27.68 months). In Cox regression analysis, mutant EGFR (p = 0.025) and lower RPA class
(p = 0.026) were associated with longer intracranial RPFS. EGFR mutation status (p = 0.061) and performance status
(p = 0.076) had a trend to predict OS.
Conclusions: Mutant EGFR in NSCLC patients is an independent prognostic factor for better treatment response
and longer intracranial RPFS following RT for brain metastases.
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Non-small cell lung cancer (NSCLC) is the leading cause
of mortality from cancer worldwide and the most com-
mon cancer responsible for brain metastases [1,2]. In
NSCLC patients with brain metastases, radiotherapy
(RT), the cornerstone of treatment, has yielded response
rates of 50% to 75% for intracranial lesions [3]. Many
prognostic factors have been explored in patients with
brain metastases [4-12] including age, performance sta-
tus, control of primary tumor, extent of extracranial dis-
ease, primary site of cancer, number of brain metastases,
and treatment modalities. These parameters have been
incorporated in commonly used indices in radiation on-
cology such as the Radiation Therapy Oncology Group
(RTOG) recursive partitioning analysis (RPA) class and
the Graded Prognostic Assessment (GPA). In addition,
incorporation of biomarkers such as the expression level
of epidermal growth factor receptor (EGFR), vascular
endothelial growth factor, and cyclooxygenase-2 has also
been correlated with treatment outcome after RT [13].
Among these biomarkers, amplification of EGFR has
been extensively studied and is regarded as a poor prog-
nostic factor in cancer [13-16]. In contrast to the radio-
resistance conferred by EGFR overexpression, the
radiosensitivity of lung cancer cells with mutant EGFR
has been demonstrated in vitro [17]. NSCLC cell lines
with EGFR mutations are more sensitive to radiation,
evidenced by increased apoptosis, than those with wild-
type EGFR. However, prior clinical studies [18,19]
attempting to investigate the relationship between EGFR
mutations and radiosensitivity in NSCLC patients with
brain metastases did not reach unanimous conclusions,
mostly due to the lack of coordinated follow-up. There-
fore, detailed analysis on the response of brain metasta-
ses to RT is imperative to clarify the role of EGFR
mutations in NSCLC. We retrospectively analyzed our
NSCLC patients who had been regularly followed up by
imaging studies after irradiation for brain metastases,
and investigated the impact of EGFR mutations on RT.
Methods
Patient eligibility
We reviewed 246 NSCLC patients who underwent EGFR
mutation testing and received cancer treatment at Wan
Fang Hospital and Taipei Medical University Hospital
between April 2003 and January 2011. Of them, 134
patients were identified to have brain metastases. The
presence of EGFR mutations was detected by either dir-
ect sequencing or the methods described previously
[20]. This study proposal was approved by our institu-
tional review board for the use of the patients’ path-
ology, medical records, and radiological images. The
inclusion criteria for the analysis were as follows:
(1) conventional brain RT as the only intracranialtreatment; and (2) consecutive brain imaging follow-up
1 to 3 months after RT, and 3 to 6 months thereafter.
Either contrast-enhanced brain magnetic resonance
imaging (MRI) or computed tomography (CT) was
required for assessment of intracranial tumors. A total
of 43 eligible patients were enrolled into this study. The
histology for most patients (n = 40) was adenocarcin-
oma, whereas 1 patient had adenosquamous carcinoma
and 2 patients had poorly differentiated carcinoma.
Clinical characteristics such as age, gender, smoking
history, performance status according to the Eastern Co-
operative Oncology Group (ECOG), RPA class, extent of
disease and the duration of EGFR tyrosine kinase inhibi-
tor (TKI) therapy of each patient were collected by
reviewing their medical records. Patients were stratified
into RPA prognostic class (I, II, or III) based on the
RTOG classification, which consists of age, performance
status, control of primary tumor, and presence of extra-
cranial metastases [6]. Controlled primary tumor was
defined as no evidence of extracranial disease progres-
sion within 1 month before brain RT. Tumor character-
istics, including number, size, and presence of
hemorrhage, were evaluated on the basis of the pre-
treatment intracranial radiological images. Cause of
death was determined by the symptoms at last follow-up
and/or radiological images within 3 months of death.
RT and assessment of RT response
The standard treatment used for brain irradiation in this
study was whole brain RT with 30 to 40 Gy in 10–20
fractions. Seventeen patients (40%) had local boost to
tumor sites up to 50–60 Gy. The radiographic response
of intracranial tumors was assessed using the Response
Evaluation Criteria in Solid Tumors (RECIST) guideline
version 1.1 [21] by comparing the pre- and post-
treatment intracranial images. Any in-field tumor pro-
gression or the appearance of new malignant lesions
denoted progressive disease. A responder was defined as
a combination of complete and partial response.
Treatment-associated toxicities were scored according to
the Common Terminology Criteria for Adverse Events
version 3.0 [22].
Statistical analysis
Categorical data are presented as number (percentage),
and continuous data are reported as mean ± standard
deviation. Comparison of categorical variables between
the mutant and wild-type EGFR groups was carried out
by Fisher’s exact test and comparison of continuous vari-
ables was performed by independent sample t-test. Mul-
tivariable logistic regression analysis was used to
examine the impact of variables on response rate.
The intracranial radiological progression-free survival
(RPFS) was counted from the first day of brain RT to
Table 1 Clinical characteristics of non-small cell lung
cancer patients with brain metastases treated with brain
RT stratified by EGFR mutation status
Characteristics Total
(N = 43)






Median (range) 59 (35-83)
<60 22 (51) 17 (57) 5 (38)
≧60 21 (49) 13 (43) 8 (62)
Gender 0.054
Female 20 (47) 17 (57) 3 (23)
Male 23 (53) 13 (43) 10 (77)
Smoking history 0.043
Never 27 (63) 22 (73) 5 (38)
Ever 16 (37) 8 (27) 8 (62)
ECOG performance status 1.60±0.88 1.60±0.89 1.62±0.87 0.959
RPA class 1.000
Class I 5 (12) 4 (13) 1 (8)
Class II 31 (72) 21 (70) 10 (77)
Class III 7 (16) 5 (17) 2 (15)
Primary tumor status 1.000
Controlled 29 (67) 20 (67) 9 (69)
Uncontrolled 14 (33) 10 (33) 4 (31)
Extracranial metastases 1.000
Absent 12 (28) 8 (27) 4 (31)
Present 31 (72) 22 (73) 9 (69)
Number of BM 0.491
≦3 14 (33) 11 (37) 3 (23)
>3 29 (67) 19 (63) 10 (77)
Size of largest BM (mm) 22.07±10.91 24.51±11.74 16.45±5.89 0.024
Hemorrhagic BM 0.019
No 32 (74) 19 (63) 13 (100)
Yes 11 (26) 11 (37) 0 (0)
Total dose 0.310
≦40 Gy2 26 (60) 20 (67) 6 (46)
>40 Gy2 17 (40) 10 (33) 7 (54)
EGFR TKI during RT 0.324
No 24 (56) 15 (50) 9 (69)
Yes 19 (44) 15 (50) 4 (31)
Type of EGFR TKI 1.000
Gefitinib 5 (26) 4 (27) 1 (25)
Erlotinib 14 (74) 11 (73) 3 (75)
Chemotherapy during RT 1.000
No 33 (77) 23 (77) 10 (77)
Yes 10 (23) 7 (23) 3 (23)
Abbreviations: ECOG Eastern Cooperative Oncology Group, RPA recursive
partitioning analysis, BM brain metastases, Gy2 biologically equivalent dose
equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.
Categorical data were presented as number (percentage) and continuous data
were presented as mean ± standard deviation.
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logical documentation of the intracranial disease status.
The overall survival (OS) was measured from the first
day of brain RT to the date of death or last follow-up.
We used the Kaplan–Meier method to calculate the
RPFS and the OS. The log-rank test and Cox regression
analysis were performed to explore the impact of vari-
ables on survival rate. The scheme of multivariable re-
gression models (both logistic and Cox models) was as
follows: a series of univariate (unadjusted) regression
analyses were performed, and those variables whose p
value is less than 0.1 in the univariate analyses were then
included in the multivariable stepwise logistic regression
analyses. Statistical significance was defined as a two-
sided p value of <0.05. All analyses were carried out
using SPSS statistical software (SPSS 15.0; SPSS Inc.,
Chicago, IL, USA).
Results
Patient and tumor characteristics
Of the 43 patients, 30 (70%) had EGFR mutations (15
had exon 19 deletions and 15 had exon 21 L858R point
mutation). The patient demographics and tumor charac-
teristics together with EGFR mutation status are listed
in Table 1. Consistent with prior studies [23-25], the
proportion of females and never-smokers was higher in
patients with mutant EGFR (57% and 73%, respectively).
The size of the largest lesion was significantly larger in
patients with mutant EGFR (24.51 ± 11.74 mm) than
those with the wild-type (16.45 ± 5.89 mm) (p = 0.024).
Hemorrhagic brain metastases (n = 11) were observed
only in patients with EGFR mutations. Of all patients,
nineteen (44%) received EGFR TKI (14 received erlotinib
and 5 received gefitinib) during the period of brain
RT. The median duration of EGFR TKI therapy in
patients with mutant EGFR (n = 15) was 215 days
(range, 25–412 days), whereas that in patients with the
wild-type (n = 4) was 32.5 days (range, 11–104 days).
Due to limited numbers in the wild-type group, statis-
tical analysis was not performed.
Radiographic response to RT
Of the 43 patients, 5 had a complete response and 25
had a partial response to RT. The overall response rate
was 70%. The rest of the patients either remained sta-
tionary in tumor size (n = 11) or had progressive intra-
cranial lesions (n = 2). The response rate was
significantly higher in patients with EGFR mutations
than those with the wild-type (80% vs. 46%; p = 0.037,
Additional file 1: Table S1). Table 2 shows the associ-
ation between clinical features and radiographic re-
sponse to brain RT. Multivariable analyses revealed that
EGFR mutation status is the only predictor for treatment
response (odds ratio: 4.67, 95% confidence interval [CI]:
Table 2 Univariate and multivariable analyses of clinical characteristics in predicting radiographic response to brain RT
Characteristics Univariate analysis Multivariable analyses
OR 95% CI of OR P OR 95% CI of OR P
Age, years (≧60 vs. <60) 0.48 0.13 to 1.81 0.277
Gender (male vs. female) 0.98 0.27 to 3.61 0.975
Smoking history (ever vs. never) 0.93 0.24 to 3.54 0.911
EGFR mutation status (positive vs. negative) 4.67 1.14 to 19.12 0.032 4.67 1.14 to 19.12 0.032
Mutant EGFR† (exon 21 vs. exon 19) 0.42 0.06 to 2.77 0.369
ECOG performance status 0.73 0.34 to 1.56 0.415
RPA class
I (reference) 1 – –
II 0.00 0.00 to ∞ 1.000
III 0.00 0.00 to ∞ 1.000
Primary tumor status (uncontrolled vs. controlled) 1.12 0.28 to 4.57 0.869
Extracranial metastases (present vs. absent) 2.05 0.51 to 8.34 0.314
Number of BM (>3 vs. ≦3) 0.89 0.22 to 3.61 0.869
Size of largest BM (mm) 1.07 0.99 to 1.15 0.091
Hemorrhagic BM (yes vs. no) 6.00 0.68 to 52.90 0.107
Total dose (>40 Gy2 vs. ≦40 Gy2) 1.07 0.28 to 4.05 0.925
EGFR TKI during RT (yes vs. no) 0.89 0.24 to 3.30 0.864
Type of EGFR TKI§ (erlotinib vs. gefitinib) 1.67 0.20 to 14.05 0.639
Chemotherapy during RT (yes vs. no) 2.00 0.36 to 11.06 0.427
Abbreviations: OR odds ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases,
Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.
† n = 30.
§ n = 19.
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ation between radiographic response and treatment mo-
dalities such as RT dose and the use of concurrent
systemic chemotherapy or EGFR TKI.
Outcome and survival
There were no ≥grade-3 RT-related toxicities in patients
treated with brain RT alone, but 4 patients experienced
major toxicities (grade-3 acneiform rash in 2 patients,
grade-3 oral mucositis in 1 patient, and grade-3 otitis
media in 1 patient) during the course of concurrent
EGFR TKI use. To minimize brain edema, oral or intra-
venous corticosteroids were administered in 39 patients
(91%) during the course of brain RT, and tapered off
thereafter. After a median follow-up of 15 months
(range: 3–39 months), 33 patients had died. Three died
of intracranial disease progression, 22 of extracranial dis-
ease progression, and 8 of other causes (4 with pneumo-
nia, 1 with urosepsis, 1 with intra-abdominal infection, 1
with upper gastrointestinal bleeding, and 1 with stroke).
The median overall survival was 15 months (95% CI:
9.61–20.39 months). The univariate analysis showed
that EGFR mutations (p = 0.061) and performance status
(p = 0.076) had a borderline impact in predicting OS
(Additional file 2: Table S2]). The median OS for
patients with or without EGFR mutations was 15 and11 months, respectively (Figure 1A). Multivariable ana-
lyses did not reveal any other clinical characteristics sig-
nificantly associated with OS.
Forty-one patients (95%) had at least 2 consecutive
follow-up images. Eleven patients (26%) were found to
have intracranial recurrence. The median intracranial
RPFS was 18 months (95% CI: 8.33–27.68 months).
Table 3 summarizes the association between different
variables and intracranial RPFS. Multivariable analyses
revealed that EGFR mutations (hazard ratio: 0.20, 95%
CI: 0.05–0.81; p = 0.025) and lower RPA class (p =
0.026) are two predictors for longer intracranial RPFS.
The median intracranial RPFS was 21 months for
patients with EGFR mutations and 12 months for those
without (Figure 1B). Also illustrated in Figure 1B, the 1-
year RPFS for patients with or without EGFR mutations
was 66% and 0% (p = 0.009), respectively.
Discussion
Our study intended to address the relationship between
EGFR mutations and RT response in NSCLC, and con-
cluded that NSCLC with mutant EGFR is more sensitive
to brain RT in patients with brain metastases. Although
EGFR overexpression is associated with radioresistance
in cancer [13-16], EGFR mutations in NSCLC have been
shown to confer radiosensitivity in vitro [17]. NSCLC
Figure 1 Survival of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation
status. (A) Overall survival. (B) Intracranial radiological progression-free survival (RPFS). Censored cases is marked by cross sign "+".
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Table 3 Univariate and multivariable analyses of clinical characteristics in predicting intracranial radiological
progression-free survival
Characteristics Univariate analysis Multivariable analyses
HR 95% CI of HR P HR 95% CI of HR P
Age, years (≧60 vs. <60) 1.07 0.35 to 3.32 0.904
Gender (male vs. female) 1.27 0.42 to 3.84 0.673
Smoking history(ever vs. never) 1.59 0.51 to 4.94 0.419
EGFR mutation status (positive vs. negative) 0.20 0.05 to 0.77 0.020 0.20 0.05 to 0.81 0.025
Mutant EGFR† (exon 21 vs. exon 19) 1.49 0.40 to 5.61 0.555
ECOG performance status 1.66 0.84 to 3.27 0.144
RPA class 0.022‡ 0.026‡
Class I (reference) 1 – – 1 – –
Class II 3.00 0.37 to 24.43 0.306 2.54 0.30 to 21.36 0.390
Class III 12.67 1.18 to 136.31 0.036 12.26 1.08 to 138.65 0.043
Primary tumor status (uncontrolled vs. controlled) 1.46 0.37 to 5.80 0.588
Extracranial metastases (present vs. absent) 0.71 0.23 to 2.19 0.549
Number of BM (>3 vs. ≦3) 1.02 0.33 to 3.14 0.970
Size of largest BM (mm) 1.01 0.97 to 1.05 0.560
Hemorrhagic BM (yes vs. no) 0.76 0.23 to 2.58 0.664
Total dose (>40 Gy2 vs. ≦40 Gy2) 0.86 0.23 to 3.28 0.825
EGFR TKI during RT (yes vs. no) 1.32 0.44 to 3.97 0.620
Type of EGFR TKI§ (erlotinib vs. gefitinib) 1.39 0.16 to 11.98 0.764
Chemotherapy during RT (yes vs. no) 0.95 0.26 to 3.46 0.940
Abbreviations: HR hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, RPA recursive partitioning analysis, BM brain metastases,
Gy2 biologically equivalent dose equal to fraction size of 2 Gy, TKI tyrosine kinase inhibitor.
† n = 30.
§ n = 19.
‡ P for linear trend.
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tion exhibit characteristics of radiosensitive phenotype,
such as delayed double-strand DNA break repair and
increased radiation-induced apoptosis. The radiosensitiv-
ity is independent of mutations in p53 or at EGFR resi-
due 790 (T790M). Upon irradiation, the clonogenic
survival for NSCLCs with EGFR mutations is reduced by
up to 500- to 1000-fold, as compared with those with
the wild-type. Clinically, previous research on the rela-
tionship between EGFR mutations in NSCLC and the re-
sponse to brain RT has discrepant findings. One study
reported that NSCLC patients with mutant EGFR have a
significantly higher response rate to whole brain RT than
those with wild-type EGFR (54% vs. 24%; p = 0.045),
judged by the interval change of neurological symptoms,
performance status, and the use of corticosteroids [19].
Nevertheless, another study showed no significant differ-
ence in brain RT response among NSCLC patients with
and without EGFR mutations (67% vs. 50%; p = 0.23) by
assessing at least 1 post-treatment brain MRI scan [18].
By using regular intracranial imaging follow-ups, our
study demonstrated that NSCLC patients with EGFR
mutations have a higher radiographic response rate. The
image-based intracranial response rate for patients withmutant EGFR was approximately 2-fold higher than that
for the wild-type group (80% vs. 46%; p = 0.037).
In this study, we also found that NSCLC with mutant
EGFR is associated with prolonged intracranial RPFS (21
vs. 12 months; p = 0.009) in patients with brain metasta-
ses, as compared with wild-type EGFR. This result
echoes previous finding that the median time to intra-
cranial progression is longer in NSCLC patients with
EGFR mutations than in those without (12.4 vs.
8.4 months; p = 0.39), judged by incidental findings of
brain MRI [18]. Our study not only demonstrates the
same trend by consecutive follow-up images but also
suggests that the superior radiosensitivity in patients
with mutant EGFR might contribute to a longer intra-
cranial RPFS. In NSCLC patients with wild-type EGFR,
more aggressive intracranial treatment for brain metas-
tases, such as stereotactic radiosurgery or neurosurgical
excision, should be considered, owing to the inferior
treatment outcome of conventional brain RT. Further-
more, our study showed that a lower pre-treatment RPA
class is associated with a longer intracranial RPFS (p =
0.026), but does not affect OS (p = 0.295). This finding
is different from prior studies [6-8,12], in which a lower
pre-treatment RPA class was associated with superior
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bias in our cohort. The majority of our patients (40 of
43) presented with adenocarcinoma and 70% had EGFR
mutations. The median OS in our study was 15 months,
which was longer than the 2 to 6 months reported in
several previous studies [6-8,26-28]. This result echoes
the findings of prior researches showing that adenocar-
cinoma [29] and EGFR mutations [18] are prognostic
factors associated with long-term survival in lung cancer
patients with brain metastases. In this patient subset, we
showed that EGFR mutation status (p = 0.061) and pre-
treatment performance status (p = 0.076) had a trend to
predict OS. With recent advances in the management of
NSCLC as well as the popularity of biomarker assess-
ment, we suggest routine assessment of EGFR mutation
status to provide personalized therapy and predict treat-
ment outcome.
On the other hand, our study did not show a superior
response to brain RT in NSCLC patients treated concur-
rently with an EGFR TKI (p = 0.864), despite the syner-
gistic effect shown by previous studies [19,30]. In
experimental models, the use of an EGFR TKI in com-
bination with RT has been shown to increase antitumor
activity by amplifying radiation-induced apoptosis and
inhibiting tumor angiogenesis [30]. In one retrospective
study, patients with concurrent EGFR TKI use were
found to have a superior response rate to brain RT. [19].
However, pharmacokinetic analyses of EGFR TKIs report
that only a tiny percentage (as low as 1%) of EGFR TKIs
can penetrate into the cerebrospinal fluid, even in
patients with brain metastases [31,32]. Therefore, an ad-
equate EGFR TKI concentration for growth inhibition of
mutant EGFR NSCLC cells might not be achieved in the
brain by standard-dose EGFR TKI administration [33].
Thus, the clinical impact of combining an EGFR TKI
with brain RT remains uncertain. In addition, variation
in EGFR mutations might affect individual responses to
EGFR TKI [34]. Although our retrospective study did
not demonstrate a synergistic effect, it highlighted that
future prospective trials are needed to elucidate the
combined effect of EGFR TKIs and brain RT.
Due to the stringent inclusion criteria and retrospect-
ive nature of this study, the patient number was rela-
tively small and most of the patients received a variety of
treatments. Despite this weakness, there was a substan-
tial difference between the survival curves of patients
with and without EGFR mutations. In addition, possible
discordance in EGFR expression between metastatic and
primary tumors should be considered, since the majority
of our samples used for EGFR mutation testing were
from primary tissues. In NSCLC, disparities in EGFR
mutations between metastatic and primary tumors were
shown to have an 8.75% to 28% discordance rate [35-
38]. However, it is not feasible to obtain brain tumorsamples for genotyping in every patient with brain me-
tastases. Recent advances in molecular imaging tech-
nologies such as positron emission tomography might be
helpful for in vivo detection of EGFR distribution or ac-
tivation in future studies [39,40]. Further prospective
studies are imperative to clarify the degree of mutant
EGFR that affects treatment outcome in NSCLC patients
with brain metastases.
Conclusions
In summary, our results suggest that mutant EGFR in
NSCLC patients is an independent prognostic factor for
better treatment response and longer intracranial RPFS
following RT for brain metastases. Therefore, before
brain RT, identification of EGFR mutation status is help-
ful in predicting treatment outcome.
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